Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme disease vaccine. Publication of this study in the peer reviewed scientific journal Vaccine titled “Vaccination…

• Neisserial OMV based Lyme vaccine elicit high antibody titers in mice
• Further evidence for Intravacc's versatile multi-disease OMV platform
• Data are published in peer reviewed journal Vaccine

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine Bilthoven, the Netherlands, 7 April 2021 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive pre-clinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray…

• Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2
• Intranasal vaccine administration has significant advantages over injectables
• OMV technology is a powerful vaccine platform for future pandemics

Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer Bilthoven, the Netherlands, 24 March 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the appointment of Nathalie Laarakker as Chief Financial Officer and member of the company’s executive management team, with effect from April 1, 2021. Mrs. Nathalie Laarakker…